A multicentre multinational randomised parallel-group placebo-controlled (double blind) and active-controlled (open) trial to compare the efficacy and safety of once weekly dosing of NNC0195-0092 with once weekly dosing of placebo and daily Norditropin FlexPro in adults with growth hormone deficiency for 35 weeks with a 53-week extension period (PRIME)
Brief description of study
The trial will compare the efficacy and safety of once weekly dosing of NNC0195-0092 with once weekly dosing of placebo and daily dosing of Norditropin®
in adult subjects with growth hormone deficiency.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
-
Conditions:
Dwarfism, Pituitary Dwarfism, growth hormone deficiency, pituitary gland
-
Age: Between 1 Years - 99 Years
-
Gender: All
Updated on
29 Sep 2022.
Study ID: 821145